Translational hematology

Section edited by Seah H. Lim 

The Translational hematology section of Journal of Translational Medicine will provide an international platform for presentation of high quality clinical and laboratory translational research, bridging the gap between basic research and pure clinical studies. The scope includes clinical and clinico-pathological investigations and fundamental research of translational potential in hematologic diseases. These include studies in red blood cells, white blood cells, platelets, coagulation, transfusion medicine, and cellular therapy.

We are also dedicated to education by providing a forum for reviews, commentaries, conference summaries and perspectives in new discovery of translational potentials. All submissions are subject to peer review and disclosure requirements. The rapid turn-around time for the processing, review, and publication of all manuscripts will ensure that any novel concepts or findings are current, timely, competitive, and relevant.

This section of the Journal of Translational Medicine will, therefore, be an up-to-date resource for physicians and scientists involved in translational research in hematology and related disciplines.

  1. Research

    Aberrant T cell responses in the bone marrow microenvironment of patients with poor graft function after allogeneic hematopoietic stem cell transplantation

    Poor graft function (PGF) is a life-threatening complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Nevertheless, whether abnormalities of T cell subsets in the bone marrow (BM)...

    Yuan Kong, Yu-Tong Wang, Xie-Na Cao, Yang Song, Yu-Hong Chen, Yu-Qian Sun, Yu Wang, Xiao-Hui Zhang, Lan-Ping Xu and Xiao-Jun Huang

    Journal of Translational Medicine 2017 15:57

    Published on: 14 March 2017

  2. Review

    Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application

    Toll-like receptor 9 (TLR9) is expressed in a variety of B-cell malignancies and works as a bridge between innate and adaptive immunity. CpG oligodeoxynucleotides (CpG ODNs), TLR9 agonists, are able to induce ...

    Ling Bai, Wei Chen, Jingtao Chen, Wei Li, Lei Zhou, Chao Niu, Wei Han and Jiuwei Cui

    Journal of Translational Medicine 2017 15:51

    Published on: 27 February 2017